Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel. METHODS: In this multicenter, double-blind, randomized trial, we compared ticagrelor (180-mg loading dose, 90 mg twice daily thereafter) and clopidogrel (300-to-600-mg loading dose, 75 mg daily thereafter) for the prevention of cardiovascular events in 18,624 patients admitted to the hospital with an acute coronary syndrome, with or without ST-segment elevation. RESULTS: At 12 months, the primary end point--a composite of death from vascular causes, myocardial infarction, or stroke--had occurred in 9.8% of patients receiving ticagrelor as compared with 11.7% of those receiving clopidogrel (hazard ratio, 0.84; 95% confidence interval [CI], 0.77 to 0.92; P<0.001). Predefined hierarchical testing of secondary end points showed significant differences in the rates of other composite end points, as well as myocardial infarction alone (5.8% in the ticagrelor group vs. 6.9% in the clopidogrel group, P=0.005) and death from vascular causes (4.0% vs. 5.1%, P=0.001) but not stroke alone (1.5% vs. 1.3%, P=0.22). The rate of death from any cause was also reduced with ticagrelor (4.5%, vs. 5.9% with clopidogrel; P<0.001). No significant difference in the rates of major bleeding was found between the ticagrelor and clopidogrel groups (11.6% and 11.2%, respectively; P=0.43), but ticagrelor was associated with a higher rate of major bleeding not related to coronary-artery bypass grafting (4.5% vs. 3.8%, P=0.03), including more instances of fatal intracranial bleeding and fewer of fatal bleeding of other types. CONCLUSIONS: In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rate of overall major bleeding but with an increase in the rate of non-procedure-related bleeding. (ClinicalTrials.gov number, NCT00391872.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In patients with ACS undergoing PCI, 12 months' DAPT with low-dose ASA and prasugrel or ticagrelor was superior to DAPT with clopidogrel in the diabetes sub-group of the respective RCTs, with a benefit-risk profile similar to the overall trial populations (Supplementary data online, Tables S12-13).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [311]
In the citing paper
“In patients with ACS for whom an early invasive strategy is planned, dual antiplatelet therapy with a P2Y12 inhibitor (ticagrelor or prasugrel) added to aspirin was superior to clopidogrel and aspirin.”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [503]
In the citing paper
“With ticagrelor given for 12 months the composite endpoint of death from vascular causes, myocardial infarction, or stroke occurred in 9.8% as compared with 11.7% of those receiving clopidogrel (HR 0.84, 95% CI 0.77-0.92;P , 0.001).No significant difference in rate of major bleeding was found.501 -503”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [503]
In the citing paper
“International trials of various pharmacotherapies have sometimes found discordant results in patients enrolled in the United States than seen in overall trial results.19–32”
From REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States (2020) · cites this paper as [19]
In the citing paper
“The reasons range from low numbers of patients enrolled in the United States to potential differences in background medical management or in patient risk profiles.”
From REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States (2020) · cites this paper as [19]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Writing Committee Members, Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., Hand, M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., et al. (2004) · Circulation · doi:10.1161/01.cir.0000134791.68010.fa · Cited by 8,356
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Self-citationBraunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D., Kupersmith, J., Levin, T. N., et al. (2000) · Circulation · doi:10.1161/01.cir.102.10.1193 · Cited by 4,487
Universal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., White, H. D., TASK FORCE MEMBERS: Chairpersons: Kristian Thygesen (Denmark), J. S. A. (., Biomarker Group: Allan S. Jaffe, C. (., ECG Group: Bernard Chaitman, C.-O. (., Imaging Group: Richard Underwood, C. (., Intervention Group: Jean-Pierre Bassand, C.-O. (., Clinical Investigation Group: Paul W. Armstrong, C. (., Global Perspective Group: Philip A. Poole-Wilson, C. (., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.187397 · Cited by 4,230
Mehta, S. R., Yusuf, S., Peters, R. J., Bertrand, M. E., Lewis, B. S., Natarajan, M. K., Malmberg, K., Rupprecht, H.-J., Zhao, F., Chrolavicius, S., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05701-4 · Cited by 2,809
急性心筋梗塞の疑いのある17187症例におけるストレプトキナーゼ静脈内投与,アスピリン経口投与,上記2つの併用または無処置の無作偽試験 ISIS-2
Dienstl, F., Backer, G. D., Cairns, J., Pedersen, F., Kala, R., Boissel, J., Schroeder, R., Horgan, J., & Tognoni, G. (1988) · The Lancet · Cited by 2,754
Mehta, S. R., Yusuf, S., & Peters, R. J. G. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00559-7 · Cited by 2,578
Research works printed but not linked: 2
- 10.1016/S0140-6736(01)05701-4 · DOI · Paper page
- 1988, Lancet, 2, 349
Cited by
Items 601–700 of 1,005
Chyrchel, B., Totoń‐Żurańska, J., Kruszelnicka, O., Chyrchel, M., Mielecki, W., Kołton‐Wróż, M., Wołkow, P. P., & Surdacki, A. (2014) · Platelets · doi:10.3109/09537104.2014.974527 · Cited by 83
Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy
Moon, J. Y., Franchi, F., Rollini, F., & Angiolillo, D. J. (2017) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2017.12.004 · Cited by 81
Incidence and outcomes of unstable angina compared with non-ST-elevation myocardial infarction
Puelacher, C., Gugala, M., Adamson, P. D., Shah, A. S. V., Chapman, A. R., Anand, A., Sabti, Z., Boeddinghaus, J., Nestelberger, T., Twerenbold, R., et al. (2019) · Heart · doi:10.1136/heartjnl-2018-314305 · Cited by 93
Komócsi, A., Vorobcsuk, A., Kehl, D., & Aradi, D. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.4026 · Cited by 83
Leonardi, S., Rao, S. V., Harrington, R. A., Bhatt, D. L., Gibson, C. M., Roe, M. T., Kochman, J., Huber, K., Zeymer, U., Madan, M., et al. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.04.008 · Cited by 79
Self-citationImpact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors
Kubica, J., Kubica, A., Jilma, B., Adamski, P., Hobl, E., Navarese, E. P., Siller-Matula, J. M., Dąbrowska, A. M., Fabiszak, T., Koziński, M., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.04.077 · Cited by 86
Leonardi, S., Mahaffey, K. W., White, H. D., Gibson, C. M., Stone, G. W., Steg, P. G., Hamm, C. W., Price, M. J., Todd, M., Dietrich, M., et al. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.02.018 · Cited by 79
Self-citationMaking Sense of Statistics in Clinical Trial Reports
Pocock, S., McMurray, J. J. V., & Collier, T. J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.014 · Cited by 86
Werns, S. W. (2012) · Yearbook of Critical Care Medicine · doi:10.1016/j.yccm.2012.01.039 · Cited by 80
ADP Platelet Hyperreactivity Predicts Cardiovascular Disease in the FHS (Framingham Heart Study)
Puurunen, M. K., Hwang, S., Larson, M. G., Vasan, R. S., O’Donnell, C. J., Tofler, G. H., & Johnson, A. D. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008522 · Cited by 81
“Effective ADP receptor inhibition has been associated with fewer cardiovascular and ischemic outcomes,(7) including in the TRITON TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel Thrombolysis in Myocardial Infarction 38)(10) and PLATO (Platelet Inhibition an…”
BackgroundLee, C. R., Sriramoju, V., Cervantes, A., Howell, L. A., Varunok, N., Madan, S., Hamrick, K., Polasek, M. J., Lee, J. A., Clarke, M. M., et al. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.117.002069 · Cited by 80
Medical and lifestyle management of peripheral arterial disease
Parvar, S., Fitridge, R., Dawson, J. A., & Nicholls, S. J. (2018) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2018.07.027 · Cited by 88
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
Costa, F., & Valgimigli, M. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1508692 · Cited by 85
Franchi, F., Rollini, F., Cho, J. R., Bhatti, M., DeGroat, C., Ferrante, E., Dunn, E. C., Nanavati, A., Carraway, E., Suryadevara, S., et al. (2015) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2015.02.030 · Cited by 83
Frailty is a short-term prognostic marker in acute coronary syndrome of elderly patients
Salinas, G. L. A., Sanmartín, M., Izco, M. P., Martín‐Asenjo, R., Mayoral, A. R., Ramos, L. S., Martín, D. M., López, A. C., Mena, M., & Gómez, J. L. Z. (2016) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872616644909 · Cited by 96
Gender-based differences in platelet function and platelet reactivity to P2Y12 inhibitors
Ranucci, M., Aloisio, T., Dedda, U. D., Menicanti, L., Vincentiis, C. D., & Baryshnikova, E. (2019) · PLoS ONE · doi:10.1371/journal.pone.0225771 · Cited by 87
“In patients under double anti-platelet therapy (DAPT) the interaction between gender and efficacy was absent [11, 12] or only demonstrated a trend towards a lower efficacy in women [13].”
BackgroundHigh lipoprotein(a): Actionable strategies for risk assessment and mitigation
Reyes‐Soffer, G., Yeang, C., Michos, E. D., Boatwright, W., & Ballantyne, C. M. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100651 · Cited by 93
“Anti-platelet/anti-coagulant therapies, such as P2Y12 receptor antagonists [128] (as monotherapy or dual antiplatelet therapy with aspirin) and/or aspirin with a low-dose anticoagulant (rivaroxaban) [129] may potentially alleviate the additional pro-thrombotic burden posed by high Lp(a).”
BackgroundPathophysiology of Bleeding and Clotting in the Cardiac Surgery Patient
Achneck, H. E., Sileshi, B., Parikh, A., Milano, C. A., Welsby, I. J., & Lawson, J. H. (2010) · Circulation · doi:10.1161/circulationaha.110.936773 · Cited by 84
Transcatheter aortic valve implantation and bleeding: incidence, predictors and prognosis
Pilgrim, T., Stortecky, S., Luterbacher, F., Windecker, S., & Wenaweser, P. (2012) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-012-0842-3 · Cited by 78
Caillon, A., Trimaille, A., Favre, J., Jesel, L., Morel, O., & Kauffenstein, G. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15566 · Cited by 81
Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Bénétos, A., Biffi, A., Boavida, J. M., Capodanno, D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.10.016 · Cited by 123
PI3K Inhibitors in Cardiovascular Disease
Eisenreich, A., & Rauch, U. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00206.x · Cited by 84
Platelet-Mediated Thrombosis: From Bench to Bedside
Gurbel, P. A., Jeong, Y.-H., Navarese, E. P., & Tantry, U. S. (2016) · Circulation Research · doi:10.1161/circresaha.115.307016 · Cited by 78
Acute Coronary Syndromes: Differences in Men and Women
Kawamoto, K. R., Davis, M. B., & Duvernoy, C. S. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0629-7 · Cited by 93
Simonsson, M., Wallentin, L. C., Alfredsson, J., Erlinge, D., Ängerud, K. H., Hofmann, R., Kellerth, T., Lindhagen, L., Ravn‐Fischer, A., Szummer, K. E., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz593 · Cited by 81
Self-citationCapodanno, D., Milluzzo, R. P., & Angiolillo, D. J. (2019) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944719893274 · Cited by 80
Cuisset, T., Grosdidier, C., Loundou, A., Quilici, J., Loosveld, M., Camoin‐Jau, L., Pankert, M., Beguin, S., Lambert, M., Morange, P., et al. (2013) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2013.04.009 · Cited by 79
Sagris, Μ., Apostolos, A., Theofilis, P., Ktenopoulos, N., Katsaros, O., Tsalamandris, S., Tsioufis, K. P., Toutouzas, K. P., & Tousoulis, D. (2024) · Biomedicines · doi:10.3390/biomedicines12040802 · Cited by 96
“At one year, the prespecified primary composite endpoint, which included cardiovascular mortality, MI, or stroke, occurred in significantly less patients treated with ticagrelor than clopidogrel (HR: 0.84, 95% CI, 0.77–0.92; p < 0.001) [104].”
BackgroundInfluentialPerceived Risk of Ischemic and Bleeding Events in Acute Coronary Syndromes
Chew, D. P., Ge, J., Parsonage, W. A., Kerkar, P. G., Sulimov, V. A., Horsfall, M. J., Mattchoss, S., & for the Perceived Risk of Ischemic and Bleeding Events in Acute Coronary Syndrome Patients (PREDICT) Study Investigators (2013) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.111.000072 · Cited by 83
Novel Antiplatelet Therapies for Atherothrombotic Diseases
Majithia, A., & Bhatt, D. L. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.310955 · Cited by 89
“The landmark PLATO (Study of Platelet Inhibition and Patient Outcomes) randomized 18 624 patients presenting with ACS to ticagrelor or clopidogrel in addition to aspirin.(26) The study demonstrated a 16% risk reduction for the composite end point of CV mortality, MI, or stroke (9.”
Alexopoulos, D. K., Xanthopoulou, I., Deftereos, S. G., Sitafidis, G., Kanakakis, J., Hamilos, M. I., Angelidis, C., Petousis, S., Stakos, D., Parissis, H., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.10.010 · Cited by 75
Floyd, C. N., Passacquale, G., & Ferro, A. (2012) · Clinical Pharmacokinetics · doi:10.2165/11630740-000000000-00000 · Cited by 79
Gender differences in cardiovascular prophylaxis: Focus on antiplatelet treatment
Giosia, P. D., Passacquale, G., Petrarca, M., Giorgini, P., Marra, A. M., & Ferro, A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.01.025 · Cited by 85
Sequential proteome alterations during genesis and progression of colon cancer
Gustafsson, M., Bruch, H.-P., Franz�n, B., Ried, T., Bergmann, T., Auer, G., J�rnvall, H., Roblick, U. J., Hirschberg, D., Habermann, J. K., et al. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4049-4 · Cited by 81
Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
Magnani, G., Bonaca, M. P., Braunwald, E., Dalby, A. J., Fox, K. A. A., Murphy, S. A., Nicolau, J. C., Ophuis, T. O., Scirica, B. M., Špinar, J., et al. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.114.001505 · Cited by 79
Self-citationBansilal, S., Bonaca, M. P., Cornel, J. H., Storey, R. F., Bhatt, D. L., Steg, P. G., Im, K., Murphy, S. A., Angiolillo, D. J., Kiss, R. G., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.050 · Cited by 76
“Indeed, in line with the data in the acute setting from the PLATO (A Comparison of Ticagrelor [AZD6140] and Clopidogrel in Patients With Acute Coronary Syndrome) trial, it is reasonable to consider ticagrelor for patients with MVD to be initiated upon presentation for an acute coronary syndrome and to be continued for…”
ResultSelf-citationKang, J., & Kim, H.-S. (2018) · Korean Circulation Journal · doi:10.4070/kcj.2018.0166 · Cited by 79
Lindholm, D., James, S. K., Gabrysch, K., Storey, R. F., Himmelmann, A., Cannon, C. P., Mahaffey, K. W., Steg, P. G., Held, C., Siegbahn, A., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.3811 · Cited by 73
Self-citationBlood cells: an historical account of the roles of purinergic signalling
Burnstock, G. (2015) · Purinergic Signalling · doi:10.1007/s11302-015-9462-7 · Cited by 76
The Year in Non–ST-Segment Elevation Acute Coronary Syndrome
Giugliano, R. P., & Braunwald, E. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.016 · Cited by 73
Clopidogrel resistance: The way forward
Ray, S. (2014) · Indian Heart Journal · doi:10.1016/j.ihj.2014.08.012 · Cited by 77
Beygui, F., Castrén, M. K., Brunetti, N. D., Ortiz, F. R., Christ, M., Zeymer, U., Huber, K., Folke, F., Svensson, L. A., Bueno, H., et al. (2015) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872615604119 · Cited by 79
Gouya, G., Arrich, J., Wolzt, M., Huber, K., Verheugt, F. W. A., Gurbel, P. A., Pirker-Kees, A., & Siller-Matula, J. M. (2013) · Stroke · doi:10.1161/strokeaha.113.002590 · Cited by 83
Dual antiplatelet therapy for secondary prevention of coronary artery disease
Degrauwe, S., Pilgrim, T., Aminian, A., Noble, S., Meier, P., & Iglesias, J. F. (2017) · Open Heart · doi:10.1136/openhrt-2017-000651 · Cited by 84
“48 Conversely, in the subgroup analysis of the PLATO trial including 5216 patients (28% of the total population) managed conservatively, the clinical benefit of ticagrelor over clopidogrel was consistent with the results in the overall study population, with a 15% reduction in the composite primary endpoint (12.0% vs…”
BackgroundInfluentialViewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified
Serebruany, V. (2011) · Thrombosis and Haemostasis · doi:10.1160/th10-12-0807 · Cited by 73
Reconstituted HDL for the acute treatment of acute coronary syndrome
Krause, B. R., & Remaley, A. T. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000020 · Cited by 80
Non–ST-Segment Acute Coronary Syndromes
Hedayati, T., Yadav, N., & Khanagavi, J. (2017) · Cardiology Clinics · doi:10.1016/j.ccl.2017.08.003 · Cited by 86
Narata, A. P., Amelot, A., Bibi, R. E., Herbreteau, D., Angoulvant, D., Gruel, Y., & Janot, K. (2018) · Neurosurgery · doi:10.1093/neuros/nyy002 · Cited by 74
External Validation of the DAPT Score in a Nationwide Population
Ueda, P., Jernberg, T., James, S. K., Alfredsson, J., Erlinge, D., Ömerovic, E., Persson, J., Ravn‐Fischer, A., Tornvall, P., Svennblad, B., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.023 · Cited by 78
“Other factors that could affect the generalizability of the DAPT score and its decision rule to new settings include how the trade-off between ischemic and bleeding risk is influenced by the type of P2Y12 inhibitor used (2,21,22), and weights assigned to bleeding and ischemic events based on the harm (e.”
BackgroundSelf-citationBonello, L., Angiolillo, D. J., Aradi, D., & Sibbing, D. (2018) · Circulation · doi:10.1161/circulationaha.118.032078 · Cited by 82
Verdoia, M., Pergolini, P., Rolla, R., Nardin, M., Schaffer, A., Barbieri, L., Marino, P. N., Bellomo, G., Suryapranata, H., & Luca, G. D. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13177 · Cited by 78
Verdoia, M., Schaffer, A., Barbieri, L., Cassetti, E., Piccolo, R., Galasso, G., Marino, P. N., Sinigaglia, F., & Luca, G. D. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000052 · Cited by 73
Goggs, R. A. N., Blais, M., Brainard, B. M., Chan, D. L., deLaforcade, A. M., Rozanski, E. A., & Sharp, C. R. (2019) · Journal of Veterinary Emergency and Critical Care · doi:10.1111/vec.12801 · Cited by 86
“37 These guidelines are based on a wealth of high-quality evidence resulting from large-scale randomized controlled trials.(38-49) Although some of these guidelines may be applicable to small animals, it is clear that the underlying physiology,(50-53) the overall burden of disease and the most frequently associated di…”
BackgroundChanges in thrombus composition and profilin-1 release in acute myocardial infarction
Ramaiola, I., Padró, T., Peña, E., Juan‐Babot, O., Cubedo, J., Martín‐Yuste, V., Sabaté, M., & Badimón, L. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu356 · Cited by 80
Angiolillo, D. J., & Ferreiro, J. L. (2010) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(10)70010-4 · Cited by 75
Physician response to implementation of genotype‐tailored antiplatelet therapy
Peterson, J., Field, J., Unertl, K. M., Schildcrout, J. S., Johnson, D., Shi, Y., Danciu, I., Cleator, J. H., Pulley, J., McPherson, J., et al. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.331 · Cited by 75
Alexopoulos, D., Xanthopoulou, I., Deftereos, S. G., Hamilos, M. I., Sitafidis, G., Kanakakis, J., Pentara, I., Vavouranakis, M., Davlouros, P. A., Hahalis, G. N., et al. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13316 · Cited by 78
Валерьевич, А. О., HARUTYUNYAN, G., Duplyakov, D. V., Константинова, Е. В., Konstantinova, N. N., Shakhnovich, R. M., Yavelov, I. S., Yakovlev, A. N., Sa, A., Alekyan, B. G., et al. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6306 · Cited by 100
Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations
Sambu, N., & Curzen, N. P. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03955.x · Cited by 77
Capodanno, D., & Angiolillo, D. J. (2014) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.113.001150 · Cited by 79
Newly Formed Reticulated Platelets Undermine Pharmacokinetically Short-Lived Antiplatelet Therapies
Armstrong, P. C. J., Hoefer, T., Knowles, R., Tucker, A. T., Hayman, M. A., Ferreira, P., Chan, M. V., & Warner, T. D. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308763 · Cited by 75
Potent P2Y 12 Inhibitors in Men Versus Women
Lau, E. S., Braunwald, E., Murphy, S. A., Wiviott, S. D., Bonaca, M. P., Husted, S., James, S. K., Wallentin, L. C., Clemmensen, P. M., Roe, M. T., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.01.028 · Cited by 77
Self-citationLee, F., Sun, C., Sung, P., Chen, K., Chua, S., Sheu, J., Chung, S., Chai, H., Chen, Y., Huang, T., et al. (2018) · Journal of Pineal Research · doi:10.1111/jpi.12489 · Cited by 72
New Directions in Antiplatelet Therapy
Ferreiro, J. L., & Angiolillo, D. J. (2012) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.111.966176 · Cited by 79
The effect of ticagrelor on growth of small abdominal aortic aneurysms—a randomized controlled trial
Wanhainen, A., Mani, K., Kullberg, J., Svensjö, S., Bersztel, A., Karlsson, L., Holst, J., Gottsäter, A., Linné, A., Gillgren, P., et al. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz133 · Cited by 73
Huang, B., Qian, Y., Xie, S., Ye, X., Chen, H., Chen, Z., Zhang, L., Xu, J., Hu, H., Ma, S., et al. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0444-5 · Cited by 75
Targeted pharmacotherapy for ischemia reperfusion injury in acute myocardial infarction
Rout, A., Tantry, U. S., Novaković, M., Sukhi, A., & Gurbel, P. A. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1787987 · Cited by 76
COVID-19 Associated Hypercoagulability: Manifestations, Mechanisms, and Management
Mazzeffi, M. A., Chow, J. H., & Tanaka, K. A. (2020) · Shock · doi:10.1097/shk.0000000000001660 · Cited by 75
“Thromboelastometry (TEM) and thromboelastography (34) show decreases in clot formation time and kinetic time, as well as increases in maximum clot firmness (MCF) and maximum amplitude (MA) (Fig.”
BackgroundWillemsen, L. M., Janssen, P. W. A., Peper, J., Hamad, M. A. S., van Straten, A. H. M., Klein, P., Hackeng, C. M., Sonker, U., Bekker, M. W. A., von Birgelen, C., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.050749 · Cited by 71
Abrignani, M. G., Gatta, L., Gabrielli, D., Milazzo, G., Francesco, V. D., Luca, L. D., Francese, M., Imazio, M., Riccio, E., Rossini, R., et al. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.11.014 · Cited by 87
Clinical importance of aspirin and clopidogrel resistance
Fehér, G., Feher, A., Pusch, G., Koltai, K., Tibold, A., Gasztonyi, B., Papp, E., Szapáry, L., Késmárky, G., & Tóth, K. (2010) · World Journal of Cardiology · doi:10.4330/wjc.v2.i7.171 · Cited by 77
Verschuren, J. J. W., Trompet, S., Wessels, J. A. M., Guchelaar, H., de Maat, M. P. M., Simoons, M. L., & Jukema, J. W. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr239 · Cited by 79
Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients With Diabetes
Alexopoulos, D. K., Xanthopoulou, I., Mavronasiou, E., Stavrou, K., Siapika, A., Tsoni, E., & Davlouros, P. A. (2013) · Diabetes Care · doi:10.2337/dc12-2510 · Cited by 74
Storey, R. F., Bliden, K. P., Ecob, R., Karunakaran, A., Butler, K. A., Wei, C., Tantry, U. S., & Gurbel, P. A. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04419.x · Cited by 71
Self-citationRinfret, S., Rodés‐Cabau, J., Bagur, R., Déry, J., Dorais, M., Larose, É., Barbeau, G. R., Gleeton, O., Nguyen, C. M., Noël, B. M., et al. (2013) · Heart · doi:10.1136/heartjnl-2012-303004 · Cited by 70
Cangrelor: a review on pharmacology and clinical trial development
Franchi, F., Rollini, F., Muñiz‐Lozano, A., Cho, J. R., & Angiolillo, D. J. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2013.837701 · Cited by 78
Pharmacodynamic effects during the transition between cangrelor and prasugrel
Schneider, D. J., Seecheran, N. A., Raza, S. S., Keating, F. K., & Gogo, P. B. (2014) · Coronary Artery Disease · doi:10.1097/mca.0000000000000158 · Cited by 70
Forecasting drug utilization and expenditure in a metropolitan health region
Wettermark, B., Persson, M. E., Wilking, N. E., Kalin, M., Korkmaz, S., Hjemdahl, P., Godman, B., Petzold, M., & Gustafsson, L. L. (2010) · BMC Health Services Research · doi:10.1186/1472-6963-10-128 · Cited by 73
Crescente, M., Menke, L., Chan, M. V., Armstrong, P. C. J., & Warner, T. D. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14196 · Cited by 83
“Aspirin is commonly given in combination with antagonists of ADP, acting at P2Y12 receptor, such as clopidogrel, prasugrel or ticagrelor (Bhatt, 2009; Gargiulo et al., 2016; Investigators TCIUaTPRET, 2001; Patrono et al., 2011; Wallentin et al., 2009; Windecker et al., 2014; Wiviott et al., 2007).”
BackgroundAdenosine and Adenosine Receptor-Mediated Action in Coronary Microcirculation
Zhang, Y., Wernly, B., Cao, X., Mustafa, S. J., Tang, Y., & Zhou, Z. (2021) · Basic Research in Cardiology · doi:10.1007/s00395-021-00859-7 · Cited by 71
Antithrombotic Therapy for Peripheral Artery Disease
Hussain, M. A., Al-Omran, M., Creager, M. A., Anand, S. S., Verma, S., & Bhatt, D. L. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.483 · Cited by 69
Time course, predictors and clinical implications of stent thrombosis following primary angioplasty
Dirksen, M. T., Spaulding, C. M., Kelbæk, H., Schalij, M. J., Thuesen, L., van der Hoeven, B., Vink, M. A., Kaiser, C. A., Musto, C., Chechi, T., et al. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-02-0092 · Cited by 69
Clinical Application of Cardiovascular Pharmacogenetics
Voora, D., & Ginsburg, G. S. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.01.067 · Cited by 75
Glycaemic Control and Vascular Complications in Diabetes Mellitus Type 2
Maranta, F., Cianfanelli, L., & Cianflone, D. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_514 · Cited by 90
Capodanno, D., & Angiolillo, D. J. (2023) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2022.10.023 · Cited by 76
Zhou, X., Huang, Y., Khalil, M. K., Wiktor, D. M., van Giezen, J. J. J., Penn, M. S., & Wang, K. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-12-0823 · Cited by 69
Hazarbasanov, D., Velchev, V., Finkov, B., Postadzhiyan, A., Kostov, E., Rifai, N., & Aradi, D. (2012) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-012-0684-z · Cited by 71
Mewhort, H. E., Turnbull, J. D., Meijndert, H. C., Ngu, J. M. C., & Fedak, P. W. M. (2013) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2013.08.005 · Cited by 76
Gherli, R., Mariscalco, G., Dalén, M., Onorati, F., Perrotti, A., Chocron, S., Verhoye, J., Gulbins, H., Reichart, D., Svenarud, P. K., et al. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.3028 · Cited by 73
A brief review on resistance to P2Y12 receptor antagonism in coronary artery disease
Warlo, E. M. K., Arnesen, H., & Seljeflot, I. (2019) · Thrombosis Journal · doi:10.1186/s12959-019-0197-5 · Cited by 73
Ferroni, P., Vazzana, N., Riondino, S., Cuccurullo, C., Guadagni, F., & Davì, G. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4324 · Cited by 68
Angiolillo, D. J., & Ferreiro, J. L. (2010) · Revista Española de Cardiología · doi:10.1016/s0300-8932(10)70010-5 · Cited by 68
Storey, R. F., Becker, R. C., Harrington, R. A., Husted, S., James, S. K., Cools, F. J. S., Steg, P. G., Khurmi, N. S., Emanuelsson, H., Lim, S. T., et al. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.07.015 · Cited by 67
Self-citationCapodanno, D., & Angiolillo, D. J. (2015) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.114.002301 · Cited by 71
Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD
Arora, S., Shemisa, K., Vaduganathan, M., Qamar, A., Gupta, A., Garg, S. K., Kumbhani, D. J., Mayo, H., Khalili, H., Pandey, A., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.470 · Cited by 75
From Early Pharmacology to Recent Pharmacology Interventions in Acute Coronary Syndromes
Szummer, K. E., Jernberg, T., & Wallentin, L. C. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.531 · Cited by 77
Self-citationIntracranial Hemorrhage During Dual Antiplatelet Therapy
Ha, A. C. T., Bhatt, D. L., Rutka, J. T., Johnston, S. C., Mazer, C. D., & Verma, S. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.07.048 · Cited by 81
Defining Heart Failure End Points in ST-Segment Elevation Myocardial Infarction Trials
Eapen, Z. J., Tang, W. H. W., Felker, G. M., Hernandez, A. F., Mahaffey, K. W., Lincoff, A. M., & Roe, M. T. (2012) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.112.966150 · Cited by 68
Self-citationThe Perioperative Management of Treatment With Anticoagulants and Platelet Aggregation Inhibitors
Schlitt, A., Jámbor, C., Spannagl, M., Gogarten, W., Schilling, T., & Zwißler, B. (2013) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2013.0525 · Cited by 91
Design of Major Randomized Trials
Pocock, S., Clayton, T. C., & Stone, G. W. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.036 · Cited by 76
Metadata
- Authors
- Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., Mahaffey, K. W., Scirica, B. M., Skene, A., Steg, P. G., Storey, R. F., & Harrington, R. A.
- Affiliations
- Uppsala University (SE)
- Duke Clinical Research Institute (US)
- Grochowski Hospital (PL)
- Brigham and Women's Hospital (US)
- AstraZeneca (Sweden) (SE)
- Aarhus University Hospital (DK)
- University Hospital Heidelberg (DE)
- University of Sheffield (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-09-10
- Volume
- 361
- Issue
- 11
- Pages
- 1045-1057
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140501627
- Cited by
- 7,117
- References
- 35
- Citations by year
- 2026: 214 · 2025: 277 · 2024: 267 · 2023: 359 · 2022: 411 · 2021: 454 · 2020: 500 · 2019: 472 · 2018: 473 · 2017: 480 · 2016: 494 · 2015: 522 · 2014: 467 · 2013: 520 · 2012: 464
- FWCI
- 253.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Open Repository and Bibliography (University of Liège) (submittedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- ticagrelor, clopidogrel, acute coronary syndrome, ST-elevation myocardial infarction, P2Y12 inhibitors, platelet aggregation inhibition, major adverse cardiovascular events, major bleeding, intracranial hemorrhage, myocardial infarction, vascular death, stroke, dual antiplatelet therapy, antiplatelet therapy, drug safety and efficacy comparison
- MeSH terms
- Clopidogrel, Ticagrelor, Adenosine, Aged, Double-Blind Method, Dyspnea, Electrocardiography, Female, Hemorrhage, Humans, Male, Myocardial Infarction, Platelet Aggregation Inhibitors, Ticlopidine, Stroke, Kaplan-Meier Estimate, Acute Coronary Syndrome, Purinergic P2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.